Cryoport, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cryoport, Inc. | |
| By: | /s/ JERRELL W. SHELTON |
| Jerrell W. Shelton | |
| President and Chief Executive Officer |
Date: March 5, 2026
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | | Title | | Date | |
|---|---|---|---|---|---|
| | | | |||
| /s/ JERRELL W. SHELTON | | President, Chief Executive Officer and Director | | March 5, 2026 | |
| Jerrell W. Shelton | | (Principal Executive Officer) | | | |
| | | | |||
| /s/ ROBERT S. STEFANOVICH | | Chief Financial Officer | | March 5, 2026 | |
| Robert S. Stefanovich | | (Principal Financial and Accounting Officer) | | | |
| | | | | | |
| /s/ DANIEL M. HANCOCK | | Director | | March 5, 2026 | |
| Daniel M. Hancock | | | | ||
| | | | |||
| /s/ ROBERT HARIRI, M.D., PH.D. | | Director | | March 5, 2026 | |
| Robert Hariri, M.D., Ph.D. | | | | ||
| | | | |||
| /s/ RAMKUMAR MANDALAM, PH.D. | | Director | | March 5, 2026 | |
| Ramkumar Mandalam, Ph.D. | | | | ||
| | | | | | |
| /s/ RAM JAGANNATH | | Director | | March 5, 2026 | |
| Ram Jagannath | | | | | |
| | | | | | |
| /s/ LINDA BADDOUR | | Director | | March 5, 2026 | |
| Linda Baddour | | | | | |
Consolidated Financial Statements
As of December 31, 2025 and 2024
Years Ended December 31, 2025, 2024 and 2023
Consolidated Financial Statements
INDEX TO FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 | F-6 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023 | F-7 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025, 2024 and 2023 | F-8 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 | F-9 |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.